TY - JOUR
T1 - Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation
AU - Saburi, Masuho
AU - Kohashi, Sumiko
AU - Kato, Jun
AU - Koda, Yuya
AU - Sakurai, Masatoshi
AU - Toyama, Takaaki
AU - Kikuchi, Taku
AU - Karigane, Daiki
AU - Yuda, Sayako
AU - Yamane, Yusuke
AU - Hashida, Risa
AU - Abe, Ryohei
AU - Nakazato, Tomonori
AU - Hirahashi, Junichi
AU - Ogata, Masao
AU - Okamoto, Shinichiro
AU - Mori, Takehiko
N1 - Funding Information:
TM received research funding from Novartis Pharma K.K. and honorarium from Astellas Pharma Inc; SO received research funding and honorarium from Novartis Pharma K.K. and Astellas Pharma Inc.
Publisher Copyright:
© 2017, The Japanese Society of Hematology.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 ± 0.80) and 4th weeks (1.53 ± 1.06) after transplantation as compared with that at the 1st week (0.93 ± 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 ± 1.06 vs. 1.13 ± 0.80; P < 0.05). These results suggest that tacrolimus increases sodium excretion after allogeneic HSCT, and that this effect is minimal with CSA.
AB - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 ± 0.80) and 4th weeks (1.53 ± 1.06) after transplantation as compared with that at the 1st week (0.93 ± 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 ± 1.06 vs. 1.13 ± 0.80; P < 0.05). These results suggest that tacrolimus increases sodium excretion after allogeneic HSCT, and that this effect is minimal with CSA.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Calcineurin inhibitor
KW - Cyclosporine A
KW - Sodium excretion
KW - Tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=85019634231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019634231&partnerID=8YFLogxK
U2 - 10.1007/s12185-017-2253-x
DO - 10.1007/s12185-017-2253-x
M3 - Article
C2 - 28516402
AN - SCOPUS:85019634231
SN - 0925-5710
VL - 106
SP - 431
EP - 435
JO - International journal of hematology
JF - International journal of hematology
IS - 3
ER -